WallStSmart

Connect Biopharma Holdings Ltd (CNTB)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Connect Biopharma Holdings Ltd generates 298% more annual revenue ($2.95M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. CNTB earns a higher WallStSmart Score of 30/100 (F).

CNTB

Avoid

30

out of 100

Grade: F

Growth: 6.3Profit: 2.5Value: 5.0Quality: 5.5
Piotroski: 1/9Altman Z: -10.67

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CNTB2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
5667.0%10/10

Revenue surging 5667.0% year-over-year

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Areas to Watch

CNTB4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$128.47M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
16.8x4/10

Trading at 16.8x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : CNTB

The strongest argument for CNTB centers on Revenue Growth, Debt/Equity. Revenue growth of 5667.0% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : CNTB

The primary concerns for CNTB are EPS Growth, Market Cap, Profit Margin.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

CNTB profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

CNTB is growing revenue faster at 5667.0% — sustainability is the question.

CNTB generates stronger free cash flow (-32M), providing more financial flexibility.

Bottom Line

CNTB scores higher overall (30/100 vs 24/100) and 5667.0% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Connect Biopharma Holdings Ltd

HEALTHCARE · BIOTECHNOLOGY · USA

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, is focused on the discovery and development of immune modulators for the treatment of severe autoimmune diseases and inflammation. The company is headquartered in Taicang, China.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?